[339 Pages Report] The global DNA diagnostics market garnered US$ 20.9 Billion in 2021 and is likely to exhibit a Y-o-Y increase of 9.6% to be valued at US$ 22.9 Billion in 2022. Owing to the growing support from various governmental organizations, the market is likely to propel to US$ 51.5 Billion by 2032. The market is projected to incline at an 8.4% CAGR during the forecast period 2022 to 2032.
Increasing cancer prevalence rates and the consequent rise in search and development by leading stakeholders, combined with rising demand for personalized medicine are expected to fuel demand for DNA diagnostics over the forecast period.
Attributes | Details |
---|---|
Global DNA Diagnostics Market CAGR (2022 to 2032) | 8.4% |
Global DNA Diagnostics Market (2032) | US$ 51.5 Billion |
Global DNA Diagnostics Market Attraction | Increasing application of DNA diagnostic in the treatment of many Infectious Diseases and Myogenic Disorder, also for Prenatal diagnosis, in preimplantation diagnosis, is expected to drive the market in the forecast period. |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Rising Incidences of Cancer to Boost DNA Diagnostics in Forthcoming Years
Owing to the growing incidences of Cancer several governmental organizations are taking initiatives to support the expansion of diagnostic centers. Also, the rising number of research and development by the leading contract research manufacturer is the primary factor driving the growth of the DNA Diagnostics market. Increasing demand for diagnosis for the treatment of oncology, and infectious diseases, is also expected to fuel the demand for the DNA diagnostics market over the forecast period.
Also, the increasing government initiatives for research and development for the treatment of chronic diseases are expected to boost the growth of the DNA diagnostics market. Technological advancement in the diagnostic and treatment process of infectious diseases propels the growth of the market in the forecasting period. The rise in demand for research and development for early detection and diagnosis of disease, and increased expenditure on the healthcare sector augmented the growth of the market.
The presence of stringent rules and regulations of various governments regarding DNA prototyping is expected to be the key factor hampering the market growth in the forecast period. Lack of awareness regarding DNA diagnostics is expected to be the key factor hampering the market growth in the forecast period. Also, the high cost of reagents and the availability of relatively affordable alternative techniques are also restraining factors influencing the market. One more challenge faced by market players is a lack of skilled professionals and inadequate capital, infrastructure is projected to limit growth through the forecast period.
At the same time, the limited availability of healthcare staff across the globe is another factor, which has an undesirable effect on the DNA diagnostics market. Also, expenses associated with DNA diagnosis are one more factor, limiting the market growth. Moreover, the lack of proper healthcare infrastructure in underdeveloped nations is a major disadvantage faced by the DNA diagnostics market.
As per the analysis, the technology sector is anticipated to hold remunerative opportunities for the global DNA Diagnostics market. Various developing countries are making significant developments in their healthcare budgets, thereby, offering lucrative opportunities to players in the market.
Increasing inclination toward genetic testing in order to determine patient health at different stages of disease development is another factor expected to fuel the demand for DNA diagnostics in the coming years. Also growing demand for newborn and pre-natal screening to detect congenital abnormalities is expected to further add to the growing demand for DNA diagnostics.
Therefore, with the rising concern for nations’ healthcare, with increased expenditure, the market is likely to witness notable opportunities for expansion in the forecast period.
DNA Diagnostics Market:
Attributes | DNA Diagnostics Market |
---|---|
CAGR (2022 to 2032) | 8.4% |
Market Value (2032) | US$ 51.5 Billion |
Growth Factor | Increasing application of DNA diagnostic in the treatment of many Infectious Diseases and Myogenic Disorder, also for Prenatal diagnosis, in preimplantation diagnosis is expected to drive the market in the forecast period. |
Opportunity | Growing healthcare concerns among various countries are expected to offer significant opportunities to the market. |
DNA Sequencing Market:
Attributes | DNA Sequencing Market |
---|---|
CAGR (2022 to 2032) | 12.6% |
Market Value (2032) | US$ 1.2 Billion |
Growth Factor | Increasing research and development activities regarding genetic disorder is expected to drive the market in the forecast period. |
Opportunity | Rising awareness of timely diagnosis and the possibility of more precise results of diagnosis is expected to give significant opportunities to the market in the assessment period. |
Oncology Market:
Attributes | Oncology Market |
---|---|
CAGR (2022 to 2032) | 9.4% |
Market Value (2032) | US$ 10 Billion |
Growth Factor | An increase in the prevalence of cancer disease and the rise in the incidence of various cancer conditions are expected to drive the market |
Opportunity | Modern developments such as advanced screening and diagnosis treatment of chronic disorders are driving the global oncology market |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Oncology to remain Dominant DNA Diagnostics Application Area
The oncology segment, by application, is projected to dominate the market during the forecast period. The segment is expected to grow at a 13.1% CAGR in the assessment period. This is simply attributed to the rising prevalence of various cancer diseases among the population such as Prostate cancer, breast cancer, colorectal cancer, and other. Increasing Research and Development investment, an increase in the geriatric population, the introduction of technologically advanced products, and a surge in the launch of new & advanced kits and reagents are the key factors that boost the growth of the segment.
Within oncology, the breast cancer segment is the major shareholder in the cancer diagnostics market, owing to the surge in the prevalence of breast cancer across the globe and the increase in the population of women under the age of 50 to 74. An increase in the number of initiatives taken by various organizations will help the industry gain traction in the coming years.
By Product Type, DNA Diagnostics Instruments to Reign Supreme
By product type, the instrument segment is likely to dominate the market in the forecast period. The government segment is anticipated to expand at a CAGR of 12.4% during the forecast period.
The growth of the segment can be attributed to the implementation of advanced technology in testing equipment. Also, the service & software segment also generated significant demand for DNA diagnostics owing to the increasing use of services and software applications in the diagnostic center.
North America to Present Lucrative Expansion Opportunities in Coming Years
North America is anticipated to lead the global DNA diagnostics market during the forecast period. The market is likely to garner US$ 18.2 Billion while exhibiting a CAGR of 8.2% from 2022 to 2032. The rapid development of the region can be attributed to the increasing presence of infectious and chronic diseases and the acceptance of new technologies of DNA diagnostics testing in this region. And also, various government initiative with increased DNA funding in the region is anticipated to propel the industry in the forecast period.
According to the World Health Organization, it is estimated that by 2030, about 23.6 million new cases of cancer will prevail worldwide, increasing government spending on healthcare in the USA. Mainly the USA & European markets, owing to the innate nature of developed healthcare infrastructure adopt advanced technology at an early stage as compared to developing economies, increasing cancer incidence rate, which follows the advanced diagnostic procedure in the USA. Furthermore, the increased popularity of self-testing kits through online websites in nations like the USA has boosted the growth of the DNA diagnostics market.
How do Growth Prospects appear across the Asia Pacific Market?
Asia Pacific is anticipated to be the fastest-growing region during the forecast period. China is likely to make the most significant contribution to developing the market. China is estimated at US$ 3.6 Billion, expanding at a 7.8% CAGR during the forecast period. The growth of the market can be attributed to the presence of evolving countries such as; India, China, Japan, and others. Also, increasing government involvement owing to rising national healthcare concerns is anticipated to positively influence the market in the coming time.
Growing healthcare availability in China, an increasing number of multi-specialty clinics and hospitals, and penetration of global players in the region are expected to fuel demand for DNA Diagnostic for research and development and advancing the diagnostic and treatment process.
In addition, Japan has been recognized as another potent player in the region. According to the analysis, the country is anticipated at US$ 2.9 Billion while recording a CAGR of 6.8% in the forecast period. The development of the regional market can be credited to the rapid development in the concerned field.UK and South Korea are estimated at US$ 2.2 Billion and US$ 1.8 Billion respectively. The growth rate of the UK is anticipated to be 7.5% while for South Korea it is estimated at 6.1% from 2022 to 2032.
Countries | Estimated CAGR |
---|---|
USA | 8.2% |
Australia | 7.5% |
China | 7.8% |
Japan | 6.8% |
South Korea | 6.1% |
Eminent players in the global DNA diagnostics market include Sysmex, Bayer Diagnostic, Roche Diagnostics, Abbott Laboratories, and Cephide Inc, among others. Recent key developments among players include:
The global DNA diagnostics market is likely to value US$ 20.9 Billion in 2021.
The global DNA diagnostics market is estimated to grow at a CAGR of 8.4% from 2022 to 2032.
The global DNA diagnostics market is predicted to procure USD 51.5 Billion from 2022 to 2032.
The Oncology segment is projected to expand at an 13.1% CAGR during the forecast period.
The instrument segment is likely to exhibit a 12.4% CAGR from 2022 to 2032.
The USA market is expected to garner US$18.2 Billion while expanding at an 8.2% CAGR from 2022 to 2032
1. Executive Summary | DNA Diagnostics Market 1.1. Global Market Outlook 1.2. Summary of Statistics 1.3. Key Market Characteristics & Attributes 1.4. FMI Analysis and Recommendations 2. Market Overview 2.1. Market Coverage 2.2. Market Definition 3. Market Risks and Trends Assessment 3.1. Risk Assessment 3.1.1. COVID-19 Crisis and Impact on DNA Diagnostics 3.1.2. COVID-19 Impact Benchmark with Previous Crisis 3.1.3. Impact on Market Value (US$ Million) 3.1.4. Assessment by Key Countries 3.1.5. Assessment by Key Market Segments 3.1.6. Action Points and Recommendation for Suppliers 3.2. Key Trends Impacting the Market 3.3. Formulation and Product Development Trends 4. Market Background 4.1. Market, by Key Countries 4.2. Market Opportunity Assessment (US$ Million) 4.2.1. Total Available Market 4.2.2. Serviceable Addressable Market 4.2.3. Serviceable Obtainable Market 4.3. Market Scenario Forecast 4.3.1. Demand in Optimistic Scenario 4.3.2. Demand in Likely Scenario 4.3.3. Demand in Conservative Scenario 4.4. Investment Feasibility Analysis 4.4.1. Investment in Established Markets 4.4.1.1. In Short Term 4.4.1.2. In Long Term 4.4.2. Investment in Emerging Markets 4.4.2.1. In Short Term 4.4.2.2. In Long Term 4.5. Forecast Factors - Relevance & Impact 4.5.1. Top Companies Historical Growth 4.5.2. Growth in Automation, By Country 4.5.3. Adoption Rate, By Country 4.6. Market Dynamics 4.6.1. Market Driving Factors and Impact Assessment 4.6.2. Prominent Market Challenges and Impact Assessment 4.6.3. Market Opportunities 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment 5. Key Success Factors 5.1. Manufacturers’ Focus on Low Penetration High Growth Markets 5.2. Banking on with Segments High Incremental Opportunity 5.3. Peer Benchmarking 6. Global Market Demand Analysis 2015 to 2021 and Forecast, 2022 to 2032 6.1. Historical Market Analysis, 2015 to 2021 6.2. Current and Future Market Projections, 2022 to 2032 6.3. Y-o-Y Growth Trend Analysis 7. Global Market Value Analysis 2015 to 2021 and Forecast, 2022 to 2032 7.1. Historical Market Value (US$ Million) Analysis, 2015 to 2021 7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Product Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Product Type, 2015 to 2021 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product Type, 2022 to 2032 8.3.1. Instruments 8.3.2. Reagents 8.3.3. Service & Software 8.4. Market Attractiveness Analysis By Product Type 9. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Technology 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis By Technology, 2015 to 2021 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Technology, 2022 to 2032 9.3.1. PCR 9.3.2. Microarray 9.3.3. In-situ Hybridization 9.3.4. Sequencing Technology 9.3.5. Mass Spectrometry 9.3.6. Others 9.4. Market Attractiveness Analysis By Technology 10. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Application 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Application, 2015 to 2021 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2022 to 2032 10.3.1. Oncology 10.3.1.1. Prostate Cancer 10.3.1.2. Breast Cancer 10.3.1.3. Colorectal Cancer 10.3.1.4. Others 10.3.2. Infectious Disease 10.3.2.1. Hepatitis B Virus 10.3.2.2. Hepatitis C Virus 10.3.2.3. HIV 10.3.2.4. TB 10.3.2.5. Chlamydia Trachomatic and Neisseria Gonorrhea (CT/NG) 10.3.2.6. HPV 10.3.2.7. Methiciline Resistant Staphylococcus Aureus (MRSA) 10.3.2.8. Others 10.3.3. Myogenic Disorder 10.3.4. Clinical Diagnostic Confirmation 10.3.5. Prenatal Diagnostics 10.3.6. Pre-implantation Diagnostics 10.3.7. Others 10.4. Market Attractiveness Analysis By Application 11. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By End User 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By End User, 2015 to 2021 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2022 to 2032 11.3.1. Point of Care 11.3.2. Diagnostic Center 11.3.3. Self-Testing/OTC 11.4. Market Attractiveness Analysis By End User 12. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Region 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis By Region, 2015 to 2021 12.3. Current Market Size (US$ Million) & Analysis and Forecast By Region, 2022 to 2032 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. Asia Pacific 12.3.5. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2015 to 2021 and Forecast 2022 to 2032 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021 13.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 13.4.1. By Country 13.4.1.1. United States of America 13.4.1.2. Canada 13.4.1.3. Rest of North America 13.4.2. By Product Type 13.4.3. By Technology 13.4.4. By End User 13.4.5. By Application 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Product Type 13.5.3. By Technology 13.5.4. By End User 13.5.5. By Application 14. Latin America Market Analysis 2015 to 2021 and Forecast 2022 to 2032 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021 14.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 14.4.1. By Country 14.4.1.1. Brazil 14.4.1.2. Mexico 14.4.1.3. Rest of Latin America 14.4.2. By Product Type 14.4.3. By Technology 14.4.4. By End User 14.4.5. By Application 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Product Type 14.5.3. By Technology 14.5.4. By End User 14.5.5. By Application 15. Europe Market Analysis 2015 to 2021 and Forecast 2022 to 2032 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021 15.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 15.4.1. By Country 15.4.1.1. Germany 15.4.1.2. France 15.4.1.3. United Kingdom 15.4.1.4. Italy 15.4.1.5. Benelux 15.4.1.6. Nordic Countries 15.4.1.7. Rest of Europe 15.4.2. By Product Type 15.4.3. By Technology 15.4.4. By End User 15.4.5. By Application 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Product Type 15.5.3. By Technology 15.5.4. By End User 15.5.5. By Application 16. Asia Pacific Market Analysis 2015 to 2021 and Forecast 2022 to 2032 16.1. Introduction 16.2. Pricing Analysis 16.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021 16.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 16.4.1. By Country 16.4.1.1. China 16.4.1.2. Japan 16.4.1.3. South Korea 16.4.1.4. Rest of Asia Pacific 16.4.2. By Product Type 16.4.3. By Technology 16.4.4. By End User 16.4.5. By Application 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Product Type 16.5.3. By Technology 16.5.4. By End User 16.5.5. By Application 17. Middle East and Africa Market Analysis 2015 to 2021 and Forecast 2022 to 2032 17.1. Introduction 17.2. Pricing Analysis 17.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021 17.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 17.4.1. By Country 17.4.1.1. GCC Countries 17.4.1.2. South Africa 17.4.1.3. Turkey 17.4.1.4. Rest of Middle East and Africa 17.4.2. By Product Type 17.4.3. By Technology 17.4.4. By End User 17.4.5. By Application 17.5. Market Attractiveness Analysis 17.5.1. By Country 17.5.2. By Product Type 17.5.3. By Technology 17.5.4. By End User 17.5.5. By Application 18. Key Countries Market Analysis 2015 to 2021 and Forecast 2022 to 2032 18.1. Introduction 18.1.1. Market Value Proportion Analysis, By Key Countries 18.1.2. Global Vs. Country Growth Comparison 18.2. US Market Analysis 18.2.1. Value Proportion Analysis by Market Taxonomy 18.2.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.2.2.1. By Product Type 18.2.2.2. By Technology 18.2.2.3. By End User 18.2.2.4. By Application 18.3. Canada Market Analysis 18.3.1. Value Proportion Analysis by Market Taxonomy 18.3.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.3.2.1. By Product Type 18.3.2.2. By Technology 18.3.2.3. By End User 18.3.2.4. By Application 18.4. Mexico Market Analysis 18.4.1. Value Proportion Analysis by Market Taxonomy 18.4.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.4.2.1. By Product Type 18.4.2.2. By Technology 18.4.2.3. By End User 18.4.2.4. By Application 18.5. Brazil Market Analysis 18.5.1. Value Proportion Analysis by Market Taxonomy 18.5.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.5.2.1. By Product Type 18.5.2.2. By Technology 18.5.2.3. By End User 18.5.2.4. By Application 18.6. Germany Market Analysis 18.6.1. Value Proportion Analysis by Market Taxonomy 18.6.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.6.2.1. By Product Type 18.6.2.2. By Technology 18.6.2.3. By End User 18.6.2.4. By Application 18.7. France Market Analysis 18.7.1. Value Proportion Analysis by Market Taxonomy 18.7.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.7.2.1. By Product Type 18.7.2.2. By Technology 18.7.2.3. By End User 18.7.2.4. By Application 18.8. Italy Market Analysis 18.8.1. Value Proportion Analysis by Market Taxonomy 18.8.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.8.2.1. By Product Type 18.8.2.2. By Technology 18.8.2.3. By End User 18.8.2.4. By Application 18.9. BENELUX Market Analysis 18.9.1. Value Proportion Analysis by Market Taxonomy 18.9.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.9.2.1. By Product Type 18.9.2.2. By Technology 18.9.2.3. By End User 18.9.2.4. By Application 18.10. UK Market Analysis 18.10.1. Value Proportion Analysis by Market Taxonomy 18.10.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.10.2.1. By Product Type 18.10.2.2. By Technology 18.10.2.3. By End User 18.10.2.4. By Application 18.11. Nordic Countries Market Analysis 18.11.1. Value Proportion Analysis by Market Taxonomy 18.11.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.11.2.1. By Product Type 18.11.2.2. By Technology 18.11.2.3. By End User 18.11.2.4. By Application 18.12. China Market Analysis 18.12.1. Value Proportion Analysis by Market Taxonomy 18.12.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.12.2.1. By Product Type 18.12.2.2. By Technology 18.12.2.3. By End User 18.12.2.4. By Application 18.13. Japan Market Analysis 18.13.1. Value Proportion Analysis by Market Taxonomy 18.13.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.13.2.1. By Product Type 18.13.2.2. By Technology 18.13.2.3. By End User 18.13.2.4. By Application 18.14. South Korea Market Analysis 18.14.1. Value Proportion Analysis by Market Taxonomy 18.14.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.14.2.1. By Product Type 18.14.2.2. By Technology 18.14.2.3. By End User 18.14.2.4. By Application 18.15. GCC Countries Market Analysis 18.15.1. Value Proportion Analysis by Market Taxonomy 18.15.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.15.2.1. By Product Type 18.15.2.2. By Technology 18.15.2.3. By End User 18.15.2.4. By Application 18.16. South Africa Market Analysis 18.16.1. Value Proportion Analysis by Market Taxonomy 18.16.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.16.2.1. By Product Type 18.16.2.2. By Technology 18.16.2.3. By End User 18.16.2.4. By Application 18.17. Turkey Market Analysis 18.17.1. Value Proportion Analysis by Market Taxonomy 18.17.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032 18.17.2.1. By Product Type 18.17.2.2. By Technology 18.17.2.3. By End User 18.17.2.4. By Application 18.17.3. Competition Landscape and Player Concentration in the Country 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Concentration 19.3. Market Share Analysis of Top Players 19.4. Market Presence Analysis 19.4.1. By Regional Footprint of Players 19.4.2. Product Footprint by Players 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Sysmex 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Sales Footprint 20.3.1.4. Strategy Overview 20.3.2. Bayer Diagnostic 20.3.2.1. Overview 20.3.2.2. Product Portfolio 20.3.2.3. Sales Footprint 20.3.2.4. Strategy Overview 20.3.3. Roche Diagnostics 20.3.3.1. Overview 20.3.3.2. Product Portfolio 20.3.3.3. Sales Footprint 20.3.3.4. Strategy Overview 20.3.4. Abbott Laboratories 20.3.4.1. Overview 20.3.4.2. Product Portfolio 20.3.4.3. Sales Footprint 20.3.4.4. Strategy Overview 20.3.5. Cephide Inc 20.3.5.1. Overview 20.3.5.2. Product Portfolio 20.3.5.3. Sales Footprint 20.3.5.4. Strategy Overview 20.3.6. Gen-probe Inc 20.3.6.1. Overview 20.3.6.2. Product Portfolio 20.3.6.3. Sales Footprint 20.3.6.4. Strategy Overview 20.3.7. Illumina, Inc 20.3.7.1. Overview 20.3.7.2. Product Portfolio 20.3.7.3. Sales Footprint 20.3.7.4. Strategy Overview 20.3.8. Thermo Fisher Scientific 20.3.8.1. Overview 20.3.8.2. Product Portfolio 20.3.8.3. Sales Footprint 20.3.8.4. Strategy Overview 20.3.9. Bio-Rad Laboratories 20.3.9.1. Overview 20.3.9.2. Product Portfolio 20.3.9.3. Sales Footprint 20.3.9.4. Strategy Overview 20.3.10. Johnson and Johnson 20.3.10.1. Overview 20.3.10.2. Product Portfolio 20.3.10.3. Sales Footprint 20.3.10.4. Strategy Overview 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports